,

Moderna, Inc. (MRNA) — Fundamental Analysis


  •   5 min reads

Table of content

Moderna is a company in genuine transition. After generating blockbuster profits during the COVID-19 vaccine era — peaking at nearly $19.3 billion in revenue in 2022 — it has seen revenue collapse as pandemic-era demand evaporated, posting steep operating losses in 2023, 2024, and the full fiscal year 2025. The encouraging news is that the most recent quarter (ending September 2026) shows the company swinging back to profitability, with positive operating and net margins for the first time in years. Moderna's balance sheet remains relatively solid, with a current ratio well above 3x and very low debt, giving it a meaningful runway to fund its pipeline. The core question for investors is whether the respiratory vaccine franchise — and the broader mRNA pipeline — can grow fast enough to restore sustainable profitability before cash reserves erode further.

Snapshot & Big Picture

Moderna went from a pre-revenue clinical-stage company to one of the most profitable biotech firms on the planet in just a few years, driven entirely by its COVID-19 vaccine, Spikevax. That extraordinary windfall — $18.5 billion in revenue in 2021 and $19.3 billion in 2022, with operating margins above 48% and 72% respectively — has since unwound sharply. By 2025, annual revenue had fallen to $1.94 billion, and the company was running an operating loss of roughly 158% of revenue. This trajectory reflects the endemic normalization of COVID boosters, pricing pressure, and a much smaller addressable market than the peak pandemic years. Moderna is now effectively rebuilding itself as a multi-product respiratory and oncology vaccine company, betting its substantial cash position and mRNA platform on a pipeline that includes RSV, influenza, and personalized cancer vaccines.

Fiscal Year Revenue EBITDA Operating Margin Net Margin
2016 $108M -$209M -206.4% -199.5%
2017 $206M -$249M -130.9% -124.3%
2018 $135M -$388M -306.0% -284.8%
2019 $60M -$515M -906.8% -853.7%
2020 $803M -$732M -95.0% -93.0%
2021 $18,471M $13,528M +72.0% +66.1%
2022 $19,263M $9,768M +48.9% +43.4%
2023 $6,848M -$3,622M -61.9% -68.8%
2024 $3,236M -$3,760M -121.9% -110.0%
2025 $1,944M -$2,863M -158.1% -145.2%

Latest Quarter Snapshot

The quarterly data for the period ending September 30, 2026 — more current than the annual figures above — offers a genuinely encouraging signal. Revenue came in at $1.31 billion for the quarter, and Moderna posted an operating margin of approximately 9.9% and a net margin of about 12.3%, meaning the company was actually profitable on both measures. EBITDA turned positive at $191 million. This is the first meaningful evidence in several years that Moderna's cost restructuring and its updated respiratory vaccine offerings may be gaining commercial traction. Capital expenditures for the quarter were $62 million, representing about 4.7% of revenue — a relatively modest level, suggesting the heavy investment phase may be moderating. The current ratio stood at 3.62x, and the debt-to-equity ratio was a low 0.086, indicating the balance sheet remains in reasonable shape.

Metric Q3 2026 (Period Ending Sep 30, 2026)
Revenue $1,313M
EBITDA $191M
Operating Margin 9.9%
Net Margin 12.3%
Current Ratio 3.62x
Debt-to-Equity 0.086
Capital Expenditures $62M (4.7% of revenue)

Profitability

Moderna's profitability history is one of the most dramatic in modern biotech. The company burned cash heavily from 2016 through 2020 — a typical pattern for a clinical-stage mRNA platform company — before its COVID vaccine transformed it into a profit machine in 2021 and 2022. The unwind has been equally dramatic: operating losses returned in 2023 and deepened each year through 2025 in margin terms, even as absolute revenue declined. The 2024 and 2025 EBITDA losses of -$3.76 billion and -$2.86 billion respectively reflect both the collapse in COVID vaccine revenue and ongoing heavy spending on R&D and commercialization of new products. The gross margin data was not separately available in the provided filings for any period. The Q3 2026 quarterly result — positive operating and net margins — is the first tangible evidence of a potential inflection point, though one quarter does not establish a trend.

Financial Health

Despite years of losses, Moderna's balance sheet has held up better than might be expected, largely because it accumulated enormous cash reserves during the 2021–2022 windfall period. The current ratio has remained above 3x in every year from 2023 through 2025, and the debt-to-equity ratio is negligible — essentially zero in 2024 and just 0.068 in 2025 — meaning the company is not reliant on leverage to fund operations.

Capital Expenditures: CapEx tells an interesting story about Moderna's reinvestment cycle. During the pre-revenue years (2016–2019), capex as a share of revenue was extremely high — ranging from 28% to 78% — but that was largely a function of tiny revenue denominators rather than massive absolute spending. As the COVID vaccine scaled, absolute capex grew to $284M in 2021 and $400M in 2022, but as a percentage of revenue those were very modest (1.5% and 2.1%), reflecting the asset-light manufacturing leverage of the period. Capital intensity then spiked sharply: capex jumped to $707M in 2023 (10.3% of revenue) and surged to $1.05 billion in 2024 (32.5% of revenue), reflecting aggressive investment in manufacturing capacity and new product infrastructure. In 2025, capex fell back to $192M (9.9% of revenue), suggesting the company pulled back on major investments as losses mounted. The most recent quarter (Q3 2026) shows capex of just $62M, or 4.7% of revenue — the lowest intensity in several years — which may indicate Moderna has right-sized its near-term investment spending as it focuses on returning to profitability.

Fiscal Year Capital Expenditures CapEx / Revenue
2016 $33M 30.6%
2017 $58M 28.4%
2018 $106M 78.3%
2019 $32M 53.1%
2020 $68M 8.5%
2021 $284M 1.5%
2022 $400M 2.1%
2023 $707M 10.3%
2024 $1,051M 32.5%
2025 $192M 9.9%
Q3 2026 (quarterly) $62M 4.7%

Growth

Moderna's revenue CAGR figures are heavily distorted by the COVID vaccine spike and its subsequent collapse, making them unusually difficult to interpret in isolation.

Window Start Year End Year Start Revenue End Revenue CAGR
3-Year FY 2022 FY 2025 $19,263M $1,944M -53.4%
5-Year FY 2020 FY 2025 $803M $1,944M +19.3%
10-Year N/A N/A N/A N/A Not available — insufficient filing history extending back 10 fiscal years from the current period

The 3-year CAGR of -53.4% captures the dramatic post-pandemic revenue collapse from the 2022 peak — a figure that reflects an extraordinary circumstance rather than fundamental business deterioration. The 5-year CAGR of +19.3% is more flattering but similarly distorted, anchoring on the low pre-vaccine 2020 base. Neither metric gives a clean picture of Moderna's underlying organic growth trajectory; the more meaningful question going forward is whether the company can sustain and grow from the revenue base it now has in a post-pandemic world. The 10-year CAGR is not available because Moderna's SEC filing history does not extend back a full decade from the current measurement period.

Source Filings

Related Posts

↑

The Noise is free. If Phil's commentary made you laugh or think, he accepts tips. No pressure — the sarcasm was complimentary.

Leave a Tip